<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vistagen Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc</link>
<description>Latest news and press releases for Vistagen Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vistagen-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d4ce78dffbe2df1211e8.webp</url>
<title>Vistagen Therapeutics Inc</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc</link>
</image>
<item>
<title>Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-receives-fda-study-may-proceed-letter-under-its-refisolone-ind-application-enabling-further-phase-2-clinical-development-for-the-treatment-of-vasomotor-symptoms-hot-flashes-due-to-menopause-1</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-receives-fda-study-may-proceed-letter-under-its-refisolone-ind-application-enabling-further-phase-2-clinical-development-for-the-treatment-of-vasomotor-symptoms-hot-flashes-due-to-menopause-1</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with</description>
</item>
<item>
<title>Vistagen to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 03 Mar 2026 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 03, 2026--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the following upcoming March investor conferences:</description>
</item>
<item>
<title>Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-to-participate-in-the-46th-annual-td-cowen-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-to-participate-in-the-46th-annual-td-cowen-healthcare-conference</guid>
<pubDate>Wed, 25 Feb 2026 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., February 25, 2026--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 46th Annual TD Cowen Healthcare Conference.</description>
</item>
<item>
<title>Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-reports-fiscal-2026-third-213000371</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-reports-fiscal-2026-third-213000371</guid>
<pubDate>Thu, 12 Feb 2026 21:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., February 12, 2026--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-report-fiscal-2026-third-133000117</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-report-fiscal-2026-third-133000117</guid>
<pubDate>Wed, 04 Feb 2026 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., February 04, 2026--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and pr</description>
</item>
<item>
<title>Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-announces-topline-results-palisade-133000285</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-announces-topline-results-palisade-133000285</guid>
<pubDate>Wed, 17 Dec 2025 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., December 17, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a statistically significant improvement on the primary endpoint of change on the Sub</description>
</item>
<item>
<title>Vistagen Appoints Nick Tressler as Chief Financial Officer</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-appoints-nick-tressler-chief-133000445</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-appoints-nick-tressler-chief-133000445</guid>
<pubDate>Mon, 01 Dec 2025 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., December 01, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025.</description>
</item>
<item>
<title>Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-reports-findings-ph80-brain-133000980</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-reports-findings-ph80-brain-133000980</guid>
<pubDate>Wed, 26 Nov 2025 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., November 26, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented exploratory data at The Menopause Society 2025 Annual Meeting in Orlando, Florida. These findings demonstrate PH80’s potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms (hot flashes) d</description>
</item>
<item>
<title>Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-reports-fiscal-2026-second-213000091</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-reports-fiscal-2026-second-213000091</guid>
<pubDate>Thu, 13 Nov 2025 21:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., November 13, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 second quarter ended September 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-report-fiscal-2026-second-133000653</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-report-fiscal-2026-second-133000653</guid>
<pubDate>Mon, 10 Nov 2025 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., November 10, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, November 13, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 second quarter ended September 30, 2025, and</description>
</item>
<item>
<title>Vistagen to Participate in Stifel Healthcare Conference 2025</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-participate-stifel-healthcare-conference-133000371</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-participate-stifel-healthcare-conference-133000371</guid>
<pubDate>Wed, 05 Nov 2025 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., November 05, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation at the Stifel Healthcare Conference on Wednesday, November 12 from 3:20-3:50 p.m. Eastern Time. The Company</description>
</item>
<item>
<title>Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-completes-palisade-3-phase-133000212</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-completes-palisade-3-phase-133000212</guid>
<pubDate>Mon, 03 Nov 2025 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., November 03, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the last patient has completed the randomized, double-blind, placebo-controlled portion of the PALISADE-3 Phase 3 clinical trial evaluating fasedienol for the acute treatment of social anxiety disorder. The op</description>
</item>
<item>
<title>Vistagen Appoints Paul Edick to its Board of Directors</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-appoints-paul-edick-board-123000574</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-appoints-paul-edick-board-123000574</guid>
<pubDate>Wed, 29 Oct 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., October 29, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen’s Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and t</description>
</item>
<item>
<title>Vistagen to Present at The Menopause Society 2025 Annual Meeting</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-present-menopause-society-2025-123000630</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-present-menopause-society-2025-123000630</guid>
<pubDate>Thu, 16 Oct 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., October 16, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data on its investigational pherine nasal spray, PH80, at The Menopause Society 2025 Annual Meeting in Orlando, Florida, on Thursday, October 23, 2025.</description>
</item>
<item>
<title>Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-present-td-cowen-5th-123000175</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-present-td-cowen-5th-123000175</guid>
<pubDate>Tue, 09 Sep 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., September 09, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry Conference. The Company will also host one-on-one meeting</description>
</item>
<item>
<title>Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-reports-fiscal-2026-first-203000461</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-reports-fiscal-2026-first-203000461</guid>
<pubDate>Thu, 07 Aug 2025 20:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., August 07, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-report-fiscal-2026-first-123000245</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-report-fiscal-2026-first-123000245</guid>
<pubDate>Thu, 31 Jul 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 31, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a cor</description>
</item>
<item>
<title>Vistagen to Present at the BTIG Virtual Biotechnology Conference</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-present-btig-virtual-biotechnology-123000559</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-present-btig-virtual-biotechnology-123000559</guid>
<pubDate>Thu, 24 Jul 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 24, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time.</description>
</item>
<item>
<title>Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-honored-outstanding-workplace-culture-123000397</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-honored-outstanding-workplace-culture-123000397</guid>
<pubDate>Tue, 15 Jul 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 15, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, has earned two prestigious workplace honors in 2025, reinforcing its commitment to employee well-being and a strong, values-driven culture. For the third consecutive year, Vistagen received Mental Health America’s Platinum Bell Seal f</description>
</item>
<item>
<title>Vistagen Appoints Elissa Cote as Chief Corporate Development Officer</title>
<link>https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-appoints-elissa-cote-chief-123000047</link>
<guid isPermaLink="true">https://6ix.com/company/vistagen-therapeutics-inc/news/vistagen-appoints-elissa-cote-chief-123000047</guid>
<pubDate>Wed, 25 Jun 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., June 25, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead the evaluation of strategic opportunities to advance Vistagen’s pherine platform toward potential commercial launc</description>
</item>
</channel>
</rss>